Oryzon Genomics S.A.

BME:ORY Rapport sur les actions

Capitalisation boursière : €103.1m

Oryzon Genomics Croissance future

Future contrôle des critères 5/6

Oryzon Genomics is forecast to grow earnings and revenue by 78.8% and 66.1% per annum respectively. EPS is expected to grow by 77% per annum. Return on equity is forecast to be -3.3% in 3 years.

Informations clés

78.8%

Taux de croissance des bénéfices

77.0%

Taux de croissance du BPA

Biotechs croissance des bénéfices36.4%
Taux de croissance des recettes66.1%
Rendement futur des capitaux propres-3.3%
Couverture par les analystes

Low

Dernière mise à jour31 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%

Oct 03
Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%

Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Jun 09
Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Apr 04
Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Jul 24
Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

May 01
Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

Feb 26
Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Jan 04
If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Prévisions de croissance des bénéfices et des revenus

BME:ORY - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20268-7-20N/A3
12/31/20255-7-17N/A3
12/31/20249-4-13N/A2
9/30/202416-5N/AN/AN/A
6/30/202412-4-14-2N/A
3/31/202415-3N/AN/AN/A
12/31/202316-4-17-1N/A
9/30/202317-4N/AN/AN/A
6/30/202317-4-21-3N/A
3/31/202317-5N/AN/AN/A
12/31/202217-5-17-2N/A
9/30/202210-3N/AN/AN/A
6/30/202214-5-15-3N/A
3/31/202212-5N/AN/AN/A
12/31/202112-5-18-4N/A
9/30/202111-4N/AN/AN/A
6/30/202110-4-17-4N/A
3/31/20217-5N/AN/AN/A
12/31/202012-4-17-6N/A
9/30/202012-4N/AN/AN/A
6/30/202013-4-16-4N/A
3/31/202013-4N/AN/AN/A
12/31/201912-4-15-4N/A
9/30/201910-4N/AN/AN/A
6/30/20199-4-11-3N/A
3/31/20198-2N/AN/AN/A
12/31/20188-1-9-1N/A
9/30/20187-2N/AN/AN/A
6/30/20186-2N/A-5N/A
3/31/20186-6N/AN/AN/A
12/31/20175-6N/A-6N/A
9/30/20176-6N/AN/AN/A
6/30/20176-6N/A-4N/A
3/31/20175-6N/AN/AN/A
12/31/20165-6N/A-5N/A
9/30/20166-5N/AN/AN/A
6/30/20166-4N/A-1N/A
3/31/20168-1N/AN/AN/A
12/31/20158-1N/A1N/A
9/30/20158-1N/AN/AN/A
6/30/20157-1N/AN/AN/A
3/31/2015112N/AN/AN/A
12/31/2014198N/A15N/A
12/31/20133-3N/AN/AN/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ORY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Bénéfices vs marché: ORY is forecast to become profitable over the next 3 years, which is considered above average market growth.

Croissance élevée des bénéfices: ORY is expected to become profitable in the next 3 years.

Chiffre d'affaires vs marché: ORY's revenue (66.1% per year) is forecast to grow faster than the Spanish market (5% per year).

Croissance élevée des revenus: ORY's revenue (66.1% per year) is forecast to grow faster than 20% per year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: ORY is forecast to be unprofitable in 3 years.


Découvrir les entreprises en croissance